GPT and Hepatic fibrosis: Baseline demographic and clinical characteristics were comparable between the two treatment groups, with no statistically significant differences in age, sex distribution, eGFR, serum creatinine, HBeAg status, baseline HBV DNA levels, ALT, AST, or liver fibrosis indices (APRI and FIB‐4) (all p > 0.05) (Table 1).